Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol

J. Rosenfeld, G. Bott-Kanner, G. Boner, A. Nissenkorn, S. Friedman, J. Ovadia, P. Merlob, S. Reisner, E. Paran, E. Zmora, Y. Biale, V. Insler

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Forty-four consecutive patients referred for treatment because of hypertension (> 150/90 mmHg) occurring during pregnancy were randomly allocated to one of two treatment groups, hydralazine alone (n = 21) or hydralazine combined with pindolol (n = 23). Satisfactory blood pressure control (diastolic pressure < 90 mmHg) was achieved in 86% of patients receiving hydralazine alone and 91% of those on combined therapy. Although the treatment did not lower the overall incidence of hypertensive complications it appeared to delay the onset of such complications until successful surgical intervention was possible. Fetal outcome was similar in both groups and there was no perinatal mortality in this high-risk population. Although blood pressure control was similar in both groups of patients, combined therapy with hydralazine and pindolol can be considered to be superior to hydralazine monotherapy, since in patients treated with the combination the incidence and intensity of troublesome side-effects was markedly lower.

Original languageEnglish
Pages (from-to)197-204
Number of pages8
JournalEuropean Journal of Obstetrics, Gynecology and Reproductive Biology
Volume22
Issue number4
DOIs
StatePublished - 1 Jan 1986
Externally publishedYes

Keywords

  • beta-blockers
  • hydralazine
  • hypertension during pregnancy

Fingerprint

Dive into the research topics of 'Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol'. Together they form a unique fingerprint.

Cite this